Mirae Asset Global Investments Co. Ltd. purchased a new position in Royalty Pharma PLC (NASDAQ:RPRX – Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 153,549 shares of the biopharmaceutical company’s stock, valued at approximately $8,961,000.
Several other institutional investors have also recently modified their holdings of RPRX. Bank of America Corp DE grew its stake in Royalty Pharma by 29.0% in the 1st quarter. Bank of America Corp DE now owns 3,495,846 shares of the biopharmaceutical company’s stock valued at $167,696,000 after acquiring an additional 786,921 shares during the period. Amundi lifted its stake in shares of Royalty Pharma by 15.3% in the 1st quarter. Amundi now owns 3,088,773 shares of the biopharmaceutical company’s stock worth $148,168,000 after acquiring an additional 409,394 shares during the period. Dorsey Asset Management LLC boosted its holdings in Royalty Pharma by 0.8% during the first quarter. Dorsey Asset Management LLC now owns 2,276,570 shares of the biopharmaceutical company’s stock worth $109,207,000 after buying an additional 17,101 shares in the last quarter. Hsbc Holdings PLC increased its holdings in Royalty Pharma by 2,562.2% during the 1st quarter. Hsbc Holdings PLC now owns 1,544,018 shares of the biopharmaceutical company’s stock valued at $74,000,000 after acquiring an additional 1,486,020 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. raised its holdings in Royalty Pharma by 0.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,273,705 shares of the biopharmaceutical company’s stock valued at $61,100,000 after acquiring an additional 5,661 shares during the last quarter. 54.35% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of equities analysts have commented on the stock. Morgan Stanley boosted their price objective on shares of Royalty Pharma from $65.00 to $67.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Weiss Ratings upgraded shares of Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, September 14th. The Goldman Sachs Group reissued a “buy” rating and issued a $66.00 target price on shares of Royalty Pharma in a research report on Thursday, August 6th. Bank of America restated a “buy” rating on shares of Royalty Pharma in a research note on Wednesday, August 5th. Finally, TD Cowen raised their price target on shares of Royalty Pharma from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Tuesday, September 8th. Eight research analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $61.57.
Read Our Latest Stock Analysis on Royalty Pharma
Key Royalty Pharma News
Here are the key news stories impacting Royalty Pharma this week:
- Positive Sentiment: Royalty Pharma raised its FY2026 royalty-receipts outlook to $3.55 billion, alongside reported quarterly growth. The stronger outlook is a key positive signal for expected royalty cash flows. Article: Royalty Pharma Q3 Results Show Growth; Raises FY26 Receipts Outlook
- Positive Sentiment: Zacks reported adjusted Q3 earnings of $1.21 per share, above its $1.18 consensus estimate and up from $1.17 a year earlier. Article: Royalty Pharma Q3 Earnings and Revenues Surpass Estimates
- Neutral Sentiment: A Seeking Alpha analysis characterized Royalty Pharma’s royalty-acquisition model as diversified and defensive, with exposure to established biopharmaceutical therapies. This is a longer-term investment perspective rather than a new company announcement. Article: Royalty Pharma: Unique, Diversified Life Science And Biopharma Pure Play
- Negative Sentiment: Reported GAAP EPS was $0.32, versus the $1.18 consensus cited in the provided results, while revenue of $690.1 million was below the cited $884.8 million estimate. The contrast with the adjusted-earnings beat reflects differing earnings measures and estimates, but the reported shortfall is a potential concern. Article: Royalty Pharma Q3 earnings results
Insiders Place Their Bets
In other Royalty Pharma news, EVP Marshall Urist sold 4,126 shares of the business’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $57.10, for a total transaction of $235,594.60. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $58.53, for a total value of $5,853,000.00. Following the completion of the sale, the executive vice president directly owned 270,401 shares in the company, valued at approximately $15,826,570.53. This represents a 27.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 208,252 shares of company stock worth $12,324,407. 18.84% of the stock is owned by corporate insiders.
Royalty Pharma Stock Performance
Shares of Royalty Pharma stock opened at $67.56 on Thursday. The firm has a market capitalization of $38.85 billion, a P/E ratio of 46.59, a P/E/G ratio of 1.82 and a beta of 0.37. Royalty Pharma PLC has a fifty-two week low of $36.03 and a fifty-two week high of $67.71. The company’s 50 day moving average price is $60.59 and its two-hundred day moving average price is $53.53. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.80 and a quick ratio of 2.80.
Royalty Pharma (NASDAQ:RPRX – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.27 by $0.05. Royalty Pharma had a return on equity of 30.01% and a net margin of 32.14%. The firm had revenue of $674.14 million during the quarter, compared to the consensus estimate of $758.93 million. On average, equities analysts forecast that Royalty Pharma PLC will post 5.29 earnings per share for the current fiscal year.
Royalty Pharma Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a dividend of $0.2350 per share. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, November 13th. Royalty Pharma’s dividend payout ratio (DPR) is currently 64.83%.
Royalty Pharma Company Profile
Royalty Pharma plc (NASDAQ:RPRX) is a biopharmaceutical royalty investment company that provides funding to life sciences companies, academic institutions, and other organizations in exchange for rights to future payments tied to approved or development-stage medicines. Its business model gives innovators access to capital while allowing Royalty Pharma to participate in the long-term commercial success of pharmaceutical products.
The company acquires and manages royalty interests across a broad range of therapeutic areas, including immunology, oncology, neuroscience, rare diseases, and infectious diseases.
Read More
- Five stocks we like better than Royalty Pharma
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
